Apogee Therapeutics, Inc.
APGE
Rang în acțiuni
#2356
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Preț acțiune
$135.07
Ultima sincronizare: 2026-09-04
Capitalizare de piață
$8.36B
Schimbare (1 zi)
0.00%
Schimbare (1 an)
144.91%
Țară
US
Tranzacționează Apogee Therapeutics, Inc. (APGE)
Categorie
Healthcare
EPS pentru Apogee Therapeutics, Inc. (APGE)
EPS la data de June 2026 TTM: $-4.34
Conform celor mai recente rapoarte financiare și prețului acțiunilor Apogee Therapeutics, Inc., EPS-ul actual al companiei (TTM) este $-4.34. La sfârșitul anului 2023, compania avea un EPS de $-1.66 o creștere față de EPS-ului din 2022, care a fost de $-0.79.
Istoricul EPS pentru Apogee Therapeutics, Inc. din 2022 până în 2026
EPS la sfârșitul fiecărui an
| An | EPS | Schimbă |
|---|---|---|
| 2026 (TTM) | $-4.34 | 31.52% |
| 2024 | $-3.30 | 98.80% |
| 2023 | $-1.66 | 110.13% |
| 2022 | $-0.79 | 0.00% |
EPS pentru companii similare sau concurente
| Companie | EPS | Diferență EPS | Țara |
|---|---|---|---|
| $17.32 | -499.08% |
US
|
|
| $-7.98 | 83.87% |
US
|
|
| $-5.29 | 21.89% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -739.17% |
NL
|
